CD36 and Its Role in Regulating the Tumor Microenvironment.
CD36
angiogenesis
lipid metabolism
tumor-associated immune cells
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
27 10 2022
27 10 2022
Historique:
received:
16
08
2022
revised:
20
10
2022
accepted:
25
10
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
CD36 is a transmembrane glycoprotein that binds to a wide range of ligands, including fatty acids (FAs), cholesterol, thrombospondin-1 (TSP-1) and thrombospondin-2 (TSP-2), and plays an important role in lipid metabolism, immune response, and angiogenesis. Recent studies have highlighted the role of CD36 in mediating lipid uptake by tumor-associated immune cells and in promoting tumor cell progression. In cancer-associated fibroblasts (CAFs), CD36 regulates lipid uptake and matrix protein production to promote tumor proliferation. In addition, CD36 can promote tumor cell adhesion to the extracellular matrix (ECM) and induce epithelial mesenchymal transition (EMT). In terms of tumor angiogenesis, CD36 binding to TSP-1 and TSP-2 can both inhibit tumor angiogenesis and promote tumor migration and invasion. CD36 can promote tumor angiogenesis through vascular mimicry (VM). Overall, we found that CD36 exhibits diverse functions in tumors. Here, we summarize the recent research findings highlighting the novel roles of CD36 in the context of tumors.
Identifiants
pubmed: 36354702
pii: curroncol29110642
doi: 10.3390/curroncol29110642
pmc: PMC9688853
doi:
Substances chimiques
Thrombospondin 1
0
CD36 Antigens
0
Thrombospondins
0
Lipids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
8133-8145Références
Cancer Res. 2009 Feb 1;69(3):1212-20
pubmed: 19176395
Nature. 2021 Nov;599(7885):485-490
pubmed: 34759321
Nat Immunol. 2014 Sep;15(9):846-55
pubmed: 25086775
Aging (Albany NY). 2020 Nov 21;13(2):1883-1897
pubmed: 33232276
Cancer Lett. 2022 Mar 1;528:59-75
pubmed: 34958892
J Transl Med. 2019 Oct 26;17(1):352
pubmed: 31655604
Nat Med. 2012 Aug;18(8):1254-61
pubmed: 22842478
Am J Pathol. 2010 Apr;176(4):2039-50
pubmed: 20167858
J Cell Sci. 2009 Feb 15;122(Pt 4):453-9
pubmed: 19155290
Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):281-6
pubmed: 26505798
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Adv Cancer Res. 2015;128:95-139
pubmed: 26216631
Nat Rev Cancer. 2003 Jun;3(6):411-21
pubmed: 12778131
Cell Rep. 2019 Dec 10;29(11):3405-3420.e5
pubmed: 31825825
Sci Transl Med. 2012 May 16;4(134):134ra62
pubmed: 22593175
Cancer Commun (Lond). 2018 May 21;38(1):27
pubmed: 29784041
J Exp Med. 2014 Jul 28;211(8):1503-23
pubmed: 25071162
Nat Commun. 2019 Mar 8;10(1):1135
pubmed: 30850595
Nanoscale. 2020 Jan 23;12(3):2133-2141
pubmed: 31913376
Cancer Metastasis Rev. 2016 Dec;35(4):645-654
pubmed: 27878502
Theranostics. 2019 Jul 9;9(17):4893-4908
pubmed: 31410189
Immunity. 2018 May 15;48(5):923-936.e4
pubmed: 29752065
Cancer Res. 2020 Apr 1;80(7):1438-1450
pubmed: 32015091
Cell Metab. 2013 Aug 6;18(2):153-61
pubmed: 23791484
Trends Mol Med. 2001 Sep;7(9):401-7
pubmed: 11530335
Genes Dev. 2016 May 1;30(9):1002-19
pubmed: 27151975
Mol Cancer Res. 2016 Mar;14(3):287-95
pubmed: 26631572
Oncoimmunology. 2020 Jun 16;9(1):1773204
pubmed: 32923132
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
J Exp Med. 2001 Sep 17;194(6):823-32
pubmed: 11560997
Cancer Discov. 2012 Sep;2(9):826-39
pubmed: 22777768
J Biol Chem. 1994 Jul 22;269(29):18985-91
pubmed: 7518447
Oncogene. 2008 Oct 6;27(45):5904-12
pubmed: 18836471
Cancer Res. 2011 Dec 15;71(24):7649-58
pubmed: 22037878
Cell Metab. 2019 Jul 2;30(1):143-156.e5
pubmed: 31031094
Cell Immunol. 2015 Nov-Dec;298(1-2):33-6
pubmed: 26344897
Sci Signal. 2009 May 26;2(72):re3
pubmed: 19471024
Nat Rev Nephrol. 2017 Dec;13(12):769-781
pubmed: 28919632
Diabetes. 2022 Feb 1;71(2):264-274
pubmed: 34737186
J Clin Invest. 2013 Jun;123(6):2447-63
pubmed: 23728179
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34145030
Mol Cancer. 2019 May 7;18(1):91
pubmed: 31064356
Cancers (Basel). 2021 Sep 08;13(18):
pubmed: 34572749
Curr Top Microbiol Immunol. 2017;403:143-170
pubmed: 28204974
FASEB J. 2019 Feb;33(2):1860-1872
pubmed: 30207797
Microvasc Res. 2007 Sep-Nov;74(2-3):90-9
pubmed: 17559888
J Cell Commun Signal. 2009 Dec;3(3-4):215-25
pubmed: 19844806
BMC Cancer. 2021 Jul 2;21(1):765
pubmed: 34215227
Immunology. 2021 Jul;163(3):293-309
pubmed: 33524161
J Clin Invest. 1989 Sep;84(3):765-72
pubmed: 2474574
Clin Transl Med. 2021 Aug;11(8):e522
pubmed: 34459127
PLoS One. 2013 Oct 28;8(10):e77604
pubmed: 24204889
Dev Cell. 2013 Jul 29;26(2):204-19
pubmed: 23871589
Immunity. 2021 Jul 13;54(7):1561-1577.e7
pubmed: 34102100
Cell. 2017 Oct 5;171(2):273-285
pubmed: 28985560
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
J Cell Biol. 1997 Aug 11;138(3):707-17
pubmed: 9245797
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Cold Spring Harb Perspect Med. 2012 May;2(5):a006627
pubmed: 22553494
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33601415
Am J Pathol. 2012 Oct;181(4):1115-25
pubmed: 22944600
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Nat Med. 2000 Jan;6(1):41-8
pubmed: 10613822
Cell Metab. 2021 May 4;33(5):1001-1012.e5
pubmed: 33691090
Hum Reprod Update. 2019 Sep 11;25(5):647-671
pubmed: 31504506
Exp Mol Med. 2014 Jun 06;46:e99
pubmed: 24903227
Cancer Res. 2013 Aug 15;73(16):4965-77
pubmed: 23913938
FASEB J. 2015 Feb;29(2):576-88
pubmed: 25395453
Breast Cancer Res Treat. 2011 Jul;128(2):337-46
pubmed: 20714802
J Biol Chem. 2009 Sep 25;284(39):26695-707
pubmed: 19640849
Reprod Biol Endocrinol. 2014 Mar 14;12:21
pubmed: 24628875
Nat Immunol. 2020 Mar;21(3):298-308
pubmed: 32066953
Cell Commun Signal. 2022 Apr 7;20(1):48
pubmed: 35392915
Nature. 2016 Mar 31;531(7596):651-5
pubmed: 26982734
Int J Mol Sci. 2020 Aug 06;21(16):
pubmed: 32781778
Cell Oncol (Dordr). 2019 Oct;42(5):591-608
pubmed: 31144271
Oncotarget. 2017 Apr 4;8(14):22550-22562
pubmed: 28186980
Oncogene. 2019 Mar;38(11):1815-1831
pubmed: 30368528
J Clin Oncol. 2005 Oct 10;23(29):7286-95
pubmed: 16145069
Pharmacol Ther. 2018 Feb;182:80-94
pubmed: 28834698
Am J Transl Res. 2020 Dec 15;12(12):7737-7761
pubmed: 33437358
Oxid Med Cell Longev. 2014;2014:360438
pubmed: 24999379
Cancer Res. 2014 Sep 15;74(18):5032-5044
pubmed: 25172842
Front Pharmacol. 2015 Oct 29;6:252
pubmed: 26578962
Oncoimmunology. 2017 Jun 30;6(10):e1344804
pubmed: 29123954
J Clin Invest. 2001 Sep;108(6):785-91
pubmed: 11560944
Cell Death Dis. 2020 Apr 23;11(4):267
pubmed: 32327627
J Dermatol Sci. 2014 May;74(2):106-15
pubmed: 24507936
NPJ Breast Cancer. 2021 Sep 24;7(1):129
pubmed: 34561446
Sci Rep. 2015 Oct 01;5:14752
pubmed: 26424075
Oncogene. 2018 Apr;37(17):2285-2301
pubmed: 29398710
J Hematol Oncol. 2017 Jan 25;10(1):33
pubmed: 28122633